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Sarcoidosis is characterized by non-caseating 
granulomas and several immunological abnormalities 
in many tissues including the lungs (pulmonary) and 
others such as skin, bone, heart (extra pulmonary)
1
. The 
aetiology of the disease is unknown although probably 
relates to an inflammatory/immune response to an 
unknown infectious agent.
1
 This leads to tissue 
damage, remodeling of airways, airway hyperactivity 
and a resultant loss of lung function. Corticosteroids 
remain the mainstay of first line treatment in 
sarcoidosis although they are not effective in all 
patients.
2,3.
Recent evidence suggests that epigenetic 
mechanisms are involved in the control of 
inflammation and immune cell function in cancer
1 
and 
in the molecular pathways implicated in other 
pulmonary disorders such as chronic obstructive lung 
disease (COPD), severe asthma and interstitial lung 
disease (IPF).
4
 These diseases are all associated with 
epithelial and mesenchymal cell remodelling within the 
airways and alveoli associated with altered patterns 
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of growth factor activity and expression; apoptosis; 
increased oxidative and endoplasmic reticulum stress; 
altered cellular senescence along with impaired 
mucociliary clearance and host defense processes in 
response to environmental agents such as pollution, 
cigarette smoke or allergens in the case of asthma.
5-7
 It 
is also evident that corticosteroid functions are under 
the regulation of epigenetic processes.
8
 
A range of epigenetic processes such as histone 
modifications, non-coding RNAs and DNA 
methylation are associated with the control of gene 
expression.
9,10 
The development and differentiation of 
most cell types including T cells 
11
 are reliant upon 
these mechanisms for efficient tissue- and cell-specific 
expression of genes. These epigenetic mechanisms do 
not act independently of each other but act in a co-
ordinate manner to regulate the induction and sustained 
expression of the myriad of epigenetic tags or marks 
that control gene expression. 
The deposition of acetylated histone marks by 
histone acetyltransferases (HATs) is associated with 
enhanced expression of immune and inflammatory 
genes.
7,12,13
 Recent evidence indicates that deposition of 
acetyl tags by HATs is not highly selective whereas 
removal of these tags by histone deacetylases 
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(HDACs), of which there are 18, is more selective.
14
 
Addition of an acetyl group alters the structure of the 
local chromatin generally allowing enhanced gene 
expression
7 
which is reversed by the action of 
HDACs.
12 
An imbalance in HAT/HDAC activity is reported in 
the airways of patients with severe asthma 
15 
and in 
COPD 
16 
and linked to the reduction in corticosteroid 
responsiveness in these two diseases
17
. In particular a 
selective loss of HDAC2 has been implicated in 
preventing corticosteroid suppression of a number of 
key inflammatory and immune genes.
18-21 
This action is 
due to both a reduced ability of the activated 
glucocorticoid receptor (GR) to remove lysing tags 
from histones at inflammatory gene promoters and due 
to changes in GR acetylation status preventing 
interaction with then nuclear factor κappa B (NF-B) 
p65.
18
 In addition to GR, many other transcription 
factors such as NF-B p65 and p53, transcription co-
regulators including PGC1, RB and c-Myc, 
inflammatory signaling pathways such as mitogen 
activated protein kinases (MAPKs), DNA repair 
proteins such as Ku 70 and the structural protein -
actin can be acetylated. This acetylation can markedly 
affect protein and cellular function.
22,23
 Complex 
interactions between acetylated non-histone proteins 
and HDACs occur, for example, activation of the 
acetylated transcription factor hypoxia-inducible factor-
1α (HIF-1α) which occurs in the lung 
microenvironment of patients with COPD, decreases 
HDAC2 expression, resulting in augmented 
inflammation and steroid resistance.
24
 
However, overall little data exists from primary 
cells/tissues regarding altered histone modifications in 
this disease. The effects of cigarette smoke on primary 
human airway epithelial cells which causes 
corticosteroid insensitivity 
5 
indicates some changes 
such as Histone H4K16 and H3K27 acetylation and 
H3K27 and DNA methylation could be examined 
preferentially in these patients and linked to gene and 
protein expression profiles.
25
  
There are few published links between the above 
epigenetic modifications or the expression of the 
various enzymes involved in depositing or removing 
these marks with corticosteroid function. This remains 
an area of intense interest. In contrast, in fibroblasts 
from patients with idiopathic pulmonary fibrosis (IPF), 
for example, there have been several studies linking 
changes in histone methylation and acetylation with 
alterations in their regulatory enzymes and the control 
of key genes including cyclooxygenase-2 (COX-2). In 
addition, the function of transforming growth factor 
beta (TGF-β) has been associated with several 
microRNAs (miRNAs) such as miR-218, miR-21, miR-
155, miR-20 and let-7d which are differentially 
expressed in fibroblasts from IPF subjects 
25
. 
Environmental stresses induce alterations in DNA 
methylation in COPD patients 22 and these can be 
mimicked in cells exposed to cigarette smoke which 
suggests that similar changes should be observed in 
sarcoidosis.25 
Indeed, the accelerated telomere shortening seen in 
sarcoidosis has been linked to earlier evidence of 
subtelomerichypomethylation.
26
 In addition, sarcoid 
patients also demonstrate higher levels of histone H4 in 
bronchial alveolar lavage (BAL) and histone H2B in 
plasma compared to healthy controls.
27
 Furthermore, 
there were suggestions that BAL histone H4 proteins 
were post-translationally modified although this needs 
to be confirmed. More studies are required in this 
direction to explore the epigenetic mechanisms 
underlying sarcoidosis epigenetics in individual 
response to corticosteroids. 
Inflammation in severe asthma, COPD and IPF has 
also been associated with altered expression of 
microRNAs and with alterations in DNA and histone 
methylation
7
. Similar to control of acetylation, 
methylation at specific residues on histone H3 for 
example is carefully controlled by the relative activities 
of histone methyltransferases (HMT)/histone 
demethylases (HDM) 
7,28,29 
and it is now clear that 
DNA methylation is also highly regulated.
30
 
Again, there is an interaction between these 
processes since altered DNA methylation of the miR-
17~92 cluster promoter results in the over expression of 
genes linked to fibroblast proliferation .
31
  
Several studies have reported alterations in 
microRNA expression profiles in severe asthma and 
COPD
32 
including changes in miR-19, -21, -27, -29a, -
126 and -146a and some of these have been associated 
with corticosteroid function including miR-145. 
33
 
Limited data exists regarding epigenetic processes 
in sarcoidosisal though miR-92b and miR-206 
expression is elevated in both the lung and lymph 
nodes of sarcoidosis patients. In contrast, miR-20a and 
miR-302c expression was elevated in lymph nodes but 
decreased in lung.
34 
In conclusion, there is increasing evidence for 
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similarities, as well as differences, in epigenetic marks 
associated with sarcoidosis and with the pathogenesis 
of other chronic inflammatory airway diseases. Further 
analysis of epigenetic changes associated with 
corticosteroid function should be addressed in future. 
Ideally, blood-based analysis should be performed and 
methods to allow mathematical deconvolution of the 
data to enable links to single cell types have been 
developed.
35
 Identification of common epigenetic 
marks between these diseases or with a lack of 
corticosteroid responsiveness in association with gene 
expression data will allow determination of key 
regulatory modules and delineation of new therapeutic 
targets
10,36 
which is critical for the welfare of these 
patients.  
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